Phathom Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Phathom Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2024.
  • Phathom Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -330 %, a 44.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -330 +261 +44.2% Sep 30, 2024
Q2 2024 -381 +166 +30.3% Jun 30, 2024
Q1 2024 -675 -210 -45.1% Mar 31, 2024
Q4 2023 -750 +389 +34.2% Dec 31, 2023
Q3 2023 -591 -1.47K -167% Sep 30, 2023
Q2 2023 -546 -824 -297% Jun 30, 2023
Q1 2023 -465 -591 -469% Mar 31, 2023
Q4 2022 -1.14K -1.22K -1422% Dec 31, 2022
Q3 2022 882 +816 +1243% Sep 30, 2022
Q2 2022 278 +225 +429% Jun 30, 2022
Q1 2022 126 +80.3 +176% Mar 31, 2022
Q4 2021 86.1 +46.7 +119% Dec 31, 2021
Q3 2021 65.7 +37.1 +130% Sep 30, 2021
Q2 2021 52.5 -28 -34.8% Jun 30, 2021
Q1 2021 45.7 Mar 31, 2021
Q4 2020 39.4 Dec 31, 2020
Q3 2020 28.5 Sep 30, 2020
Q2 2020 80.5 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.